[ad_1]
End-of-study data from CLEOPATRA confirm the long-term efficacy of Genetech's Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy in patients with HER2-positive metastatic bad cancer. still treated.
Patients treated with the Perjeta combination experienced an additional 16.5 months on average compared to the control group not receiving Perjeta, an improvement considered "unprecedented" for this type of cancer.
The findings were presented at the 2019 annual meeting of the ASCO (American Society of Clinical Oncology) by Sandra M. Swain, MD, FASCO, Breast Cancer Specialist and Professor at Georgetown University.
The test data were highlighted in the poster "End-of-study study of the randomized, double-blind, placebo-controlled (Pla) CLEOPATRA Phase II trial of first-line pertuzumab (P), trastuzumab (H) and docetaxel (D) in patients (pts) with HER2-positive metastatic bad cancer (MBC)."
"Our science-based approach has been transforming bad cancer treatment standards for over 20 years and we are pleased to present data from a Perjeta study that demonstrated unprecedented benefit in terms of survival for patients with bad cancer." from an advanced disease to HER2-positive, "Sandra Horning, MD, Roche's chief medical officer and head of global product development, said in a <a href =" https
[ad_2]
Source link
